Half-year report · HY
4544.TEDINET S100X1GC
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥124.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥243.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥120.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥2.3bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥956m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥305m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥4.7bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.3bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥187m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥1.6bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥205m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥821m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥142m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | −¥821m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥274.0bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥279.6bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥291.4bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥138.9bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥142.3bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥135.1bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥137.3bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥136.1bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥39.6bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥40.9bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥39.6bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥40.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥47.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥39.9bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥6.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥22.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥2.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥16.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥9.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥5.8bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥10.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥3.61 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.6 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-14.47 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥3.61 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 49.2% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.0% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥2.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥2.3bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥2.7bn |
| Clinical Lab Testing Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥79.4bn |
| Clinical Lab Testing Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥79.2bn |
| Clinical Lab Testing Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥249m |
| Clinical Lab Testing Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥930m |
| In Vitro Diagnostics Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥31.4bn |
| In Vitro Diagnostics Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥29.4bn |
| In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥2.0bn |
| In Vitro Diagnostics Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥4.8bn |
| Sterilization And Related Servicesreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥15.9bn |
| Sterilization And Related Servicesreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥15.8bn |
| Sterilization And Related Servicesreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥90m |
| Sterilization And Related Servicesreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.2bn |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥126.7bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥124.4bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥2.3bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥5.1bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥2.5bn |
| Clinical Lab Testing Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥76.7bn |
| Clinical Lab Testing Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥76.5bn |
| Clinical Lab Testing Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥205m |
| Clinical Lab Testing Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥2.9bn |
| In Vitro Diagnostics Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥31.2bn |
| In Vitro Diagnostics Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥29.0bn |
| In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.2bn |
| In Vitro Diagnostics Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥5.5bn |
| Sterilization And Related Servicesreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥14.5bn |
| Sterilization And Related Servicesreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥14.4bn |
| Sterilization And Related Servicesreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥9m |
| Sterilization And Related Servicesreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥879m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥122.4bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥120.0bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.4bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥3.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 524
| Item | Context | Value | Unit |
|---|---|---|---|
| Retirement benefit expenses sga | Prior1InterimDuration | 525000000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 479000000 | JPY |
| Depreciation sga | Prior1InterimDuration | 2673000000 | JPY |
| Depreciation sga | InterimDuration | 3285000000 | JPY |
| Amortization of goodwill sga | Prior1InterimDuration | 230000000 | JPY |
| Amortization of goodwill sga | InterimDuration | 329000000 | JPY |
| Commission fee sga | Prior1InterimDuration | 6369000000 | JPY |
| Commission fee sga | InterimDuration | 7727000000 | JPY |
| Research and development expenses sga | Prior1InterimDuration | 5187000000 | JPY |
| Research and development expenses sga | InterimDuration | 5545000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 76518000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 29019000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 14448000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReportableSegmentsMember | 119987000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 119987000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 205000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 2214000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 9000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReportableSegmentsMember | 2428000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | -2428000000 | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 76723000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 31234000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 14457000000 | JPY |
| Net sales | Prior1InterimDuration_ReportableSegmentsMember | 122415000000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | -2428000000 | JPY |
| Net sales | Prior1InterimDuration | 119987000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | -2892000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 5481000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 879000000 | JPY |
| Operating income | Prior1InterimDuration_ReportableSegmentsMember | 3468000000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | -2511000000 | JPY |
| Operating income | Prior1InterimDuration | 956000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 79190000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 29435000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 15766000000 | JPY |
| Revenues from external customers | InterimDuration_ReportableSegmentsMember | 124392000000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 124392000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 249000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 1990000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 90000000 | JPY |
| Transactions with other segments | InterimDuration_ReportableSegmentsMember | 2330000000 | JPY |
| Transactions with other segments | InterimDuration_ReconcilingItemsMember | -2330000000 | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 79439000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 31426000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 15856000000 | JPY |
| Net sales | InterimDuration_ReportableSegmentsMember | 126722000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |